


Claims for 10/016/276  
My case

# Claims

1. A compound of the formula



wherein

R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl;

R<sup>1</sup> is hydrogen or halogen; or


R and R<sup>1</sup> when adjacent, together with the ring carbon atoms to which they are attached are  
-CH=CH-CH=CH-;

R<sup>2</sup> and R<sup>2'</sup> are hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano; or

R<sup>2</sup> and R<sup>2'</sup> when adjacent, together with the ring carbons to which they are attached are  
-CH=CH-CH=CH-, unsubstituted or substituted by one or two substituents selected  
from lower alkyl or lower alkoxy;

R<sup>3</sup> and R<sup>3'</sup> are hydrogen, lower alkyl or cycloalkyl;

R<sup>4</sup> and R<sup>4'</sup> together with the N-atom to which they are attached form a 5 member nitrogen  
containing heterocyclic ring of the structure



said heterocyclic ring having 0 or 1 additional hetero-atoms selected from sulfur,  
nitrogen and oxygen, said additional hetero-sulfur atom being a sulfonyl moiety;

R<sup>5</sup> is hydrogen, hydroxy, lower alkyl, -lower alkoxy, -(CH<sub>2</sub>)<sub>m</sub>OH, -COOR<sup>3</sup>,  
-CON(R<sup>3</sup>)<sub>2</sub>, -N(R<sup>3</sup>)CO-lower alkyl or -C(O)R<sup>3</sup>;

R<sup>6</sup> is lower alkyl;

X is -C(O)N(R<sup>6</sup>)-, -N(R<sup>6</sup>)C(O)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -O(CH<sub>2</sub>)<sub>m</sub>-;

n is 0, 1, 2, 3 or 4; and



m is 1, 2 or 3;


or a pharmaceutically acceptable acid addition salt thereof.

2. The compound of claim 1 wherein R is methyl.

3. The compound of claim 1 wherein R is chloro.

4. The compound of claim 1 wherein R<sup>2</sup> and R<sup>2'</sup> are adjacent and taken together with the rig carbons to which they are attached to form the group -CH=CH-CH=CH-.

5. The compound of claim 1 having the structure




le

6. The compound of claim 5 wherein R is methyl.

7. The compound of claim 5 wherein R is chloro.

8. The compound of claim 5 wherein R<sup>2</sup> and R<sup>2'</sup> are adjacent and taken together with the rig carbons to which they are attached to form the group -CH=CH-CH=CH-.

9. The compound of claim 1 having the structure



Id

10. The compound of claim 9 wherein R is methyl.
11. The compound of claim 9 wherein R is chloro.
12. The compound of claim 9 wherein R<sup>2</sup> and R<sup>2'</sup> are adjacent and taken together with the rig carbons to which they are attached to form the group -CH=CH-CH=CH-.
13. The compound (RS)-6-[3-(acetyl-methyl-amino)-1-oxo-pyrrolidin-1-yl]-N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-4-o-tolyl-nicotinamide.
14. A method of inhibiting NK-1 receptor in an individual comprising administering to the individual compound of formula I according to claim 1.
15. A method of treating a disease responsive to antagonist modulation of the NK-1 receptor in a patient in need of such treatment comprising administering an effective amount of the compound of formula I according to claim 1 to the patient.

\*\*\*\*